In vitro metabolism of glycyrrhetic acid by human cytochrome P450

Yaoxue Xuebao

Volumn 46, Issue 1, 2011, Pages 81-87

  Liu, Li ^a   Xiao, Juan ^a   Peng, Zhi Hong ^a   Chen, Yong ^a  

^a HUBEI UNIVERSITY   (China)

Author keywords

Cytochrome P450; Glycyrrhetic acid; Human liver microsome; Metabolism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLYCYRRHETINIC ACID;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; GLYCYRRHETINIC ACID; GLYCYRRHIZA; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PLANT ROOTS; PLANTS, MEDICINAL;

EID: 79551503789     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kao TC, Shyu MH, Yen GC. Glycyrrhizic acid and 18beta-glycyrrhetinic acid inhibit inflammation via PI3K/Akt/GSK3beta signaling and glucocorticoid receptor activation [J]. J Agric Food Chem, 2010, 58: 8623-8629.
2. Sasaki H, Suzuki N, Alshwaimi E, et al. 18β-Glycyrrhetinic acid inhibits periodontitis via glucocorticoid-independent nuclear factor-κB inactivation in interleukin-10-deficient mice [J]. J Periodontal Res, 2010, 45: 757-763.
3. Vlietinck AJ, Bruyne TD, Apers S, et al. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection [J]. Planta Med, 1998, 64: 97-109. (Pubitemid 28153266)
4. Clercq ED. Current lead natural products for the chemotherapy of human immunodefiency virus (HIV) infection [J]. Med Res Rev, 2000, 20: 323-349.
5. Pokrovskii AG, Pliasunova OA, Gashnikova NM, et al. Chronically HIV-1 infected human monocyte culture U937 as a model for assessing the efficacy of anti-HIV agents [J]. Vopr Virusol, 2001, 46: 38-42.
6. Sasaki H, Takei M, Kobayashi M, et al. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients [J]. Pathobiology, 2002/2003, 70: 229-236.
7. Huang W, Wang W, Wang P, et al. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl 1-glutamate) micelles for liver targeting therapy [J]. Acta Biomater, 2010, 6: 3927-3935.
8. Xiao Y, Xu J, Mao C, et al. 18 Beta-glycyrrhetinic acid ameliorates acute Propionibacterium acnes-induced liver injury through inhibition of macrophage inflammatory protein-1 alpha [J]. J Biol Chem, 2010, 285: 1128-1137.
9. Hirabayashi K, Iwata S, Matsumoto H, et al. Antiviral activities of glycyrrhizin and its modified compounds against human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1) in vitro [J]. Chem Pharm Bull, 1991, 39: 112-115.
10. Kim YS, Kim JJ, Cho KH, et al. Biotransformation of ginsenoside Rb1, crocin, amygdalin, geniposide, puerarin, ginsenoside Re, hesperidin, poncirin, glycyrrhizin, and baicalin by human fecal microflora and its relation to cytotoxicity against tumor cells [J]. J Microbiol Biotechnol, 2008, 18: 1109-1114.
11. Gao K, Wei Y, Yang J, et al. CYP3A1/2 and 2C9/10 in rat liver microsomes mediate 22〈alpha〉-and 24-hydroxylation of 18〈alpha〉- glycyrrhetic acid [J]. Chin J Clin Pharmacol Ther, 2007, 12: 1255-1260.
12. He F, Bi HC, Xie ZY, et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids [J]. Rapid Commun Mass Spectrom, 2007, 21: 635-643.
13. Wang J, Pitarque M, Ingelman SM. 3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression [J]. Biochem Biophys Res Commun, 2006, 340: 491-497. (Pubitemid 43021775)
14. Weaver R, Graham KS, Beattie IG, et al. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry-multiple reaction monitoring technology in a cassette incubation [J]. Drug Metab Dispos, 2003, 31: 955-966.
15. Kim KB, Seo KA, Yoon YJ, et al. In vitro metabolism of a novel PPAR agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s [J]. Xenobiotica, 2008, 38: 1165-1176.
16. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective [J]. Drug Metab Dispos, 2003, 31: 815-832.
17. Tang J, Usmani KA, Hodgson E, et al. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam [J]. Chem Biol Interact, 2004, 147: 319-329.
18. Kim H, Yoon YJ, Kim H, et al. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028 [J]. Toxicol Lett, 2006, 166: 105-114.
19. Kim KA, Kim MJ, Park JY, et al. Stereoselective metabolism of Lansoprazole by human liver cytochrome P450 enzymes [J]. Drug Metab Dispos, 2003, 31: 1227-1234. (Pubitemid 37152973)
20. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities [J]. Drug Metab Dispos, 2004, 32: 647-660. (Pubitemid 38668158)
21. Yao HT, Chang YW, Lan SJ, et al. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes [J]. Life Sci, 2006, 79: 2432-2440.
22. Li XY, Chen XY, Li Q, et al. Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry [J]. J Chromatogr B, 2007, 852: 128-137.
23. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics [J]. Cell Mol Life Sci, 2001, 58: 737-747.
24. Rendic S, Di CFJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and Inhibitors [J]. Drug Metab Rev, 1997, 29: 413-580.
25. Delgoda R, Westlake AC. Herbal interactions involving cytochrome P450 enzymes: a mini review [J]. Toxicol Rev, 2004, 23: 239-249.
26. Scripture CD, Figg WD. Drug interactions in cancer therapy [J]. Nat Rev Cancer, 2006, 6: 546-558.
27. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions [J]. Adv Pharmacol, 1997, 43: 7-35.
28. Halpert JR. Structural basis of selective cytochrome P450 inhibition [J]. Ann Rev Pharmacol, 1995, 35: 29-53.
29. Zhang QH, Li Y. Quantitative prediction of in vivo drug-drug interactions based on in vitro inhibition or/and induction data for CYP3A4 [J]. Acta Pharm Sin, 2010, 45: 952-959.
30. Ying JY, Gu SJ, Yao TW. Research progress on interaction between luteolin (glucosides) and drug-metabolising enzyme [J]. Acta Pharm Sin, 2008, 43: 335-342.